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2013= 608 756€ /34.09%; max2013= 2 394 665€ ; min2009= 1 785 909€ ; AVG= 2 015 533€ ; 
Mean= 1 983 142€ ; SD= 19 398). The share of MDCT on the patient supplements 
of MD slightly increased (MDCT/MD2009= 3.74%; MDCT/MD2013= 5.42%; Δ MDCT/
MD2009-2013= 1.68%). The total patient supplements increased (Δ 2009-2013= 165 
257€ /141.27%; max2013= 282 248€ ; min2009= 116 991€ ; AVG= 181 612€ ; Mean= 160 
686€ ; SD= 67 547). ConClusions: MDCT have supplements for patients that greatly 
exceed the reimbursement from the resources of public health insurance. Legislative 
changes in the list of categorized medical devices brought gradual increase patient´s 
co-payment for MDCT.
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objeCtives: Incontinence constitutes not only a serious medical problem, but 
a problem with a significant financial burden both public health insurance and 
patient. Performed analysis can serve as a base for legislative measures in the area 
of price regulation and management of their rational prescription for the benefit 
of the patient. The medical devices for patient with incontinence (MDI) are almost 
completely reimbursed from Health insurance funds respecting quantitative lim-
its. Methods: The target of the work was to analyse the data from paid data-
bases of Slovak authority National Center for Health Information that collects the 
outputs of provided health care. The data were focused on totally or partly reim-
bursed medical devices from public health insurance funds. The selected group 
was medical devices for people with diabetes (1.1. 2009 - 31.12. 2013). It was used 
basic and advanced statistic processing by Microsoft Excel. Results: Referring 
to the Center for Health Information, in the observed period, the share of MDI on 
total consumption of MD increased (MDI/MD2009= 78.50%; MDI/MD2013= 86.77%; 
Δ MDI/MD2009-2013= 8.27%). The total quantitative consumption MDI also increased 
(Δ 2009-2013= 27 186 148pcs/41.47%; max2013= 92 748 295pcs; min2009= 65 562 
147pcs; AVG= 79 331 861pcs; Mean= 79 160 957pcs; SD= 10 905 444). The share of 
MDI on total reimbursement of MD stagnated (MDI/MD2009= 30.61%; MDI/MD2013= 
30.65%; Δ MDI/MD2009-2013= 0.04%). The total reimbursement in the observed period 
increased (Δ 2009-2013= 8 468 173€ /22.19%; max2013= 47 979 262€ ; min2009= 39 266 
765€ ; AVG= 42 961 151€ ; Mean= 43 350 989€ ; SD= 3 684 081). The total patient supple-
ments also decreased (Δ 2009-2013= -4 001€ /-67.02%; max2009= 5 970€ ; min2013= 1 
969€ ; AVG= 6 475€ ; Mean= 2 125€ ; SD= 8 257). ConClusions: According to the Health 
Insurance Funds annual reports the increase of costs was due to the change in 
therapies that require the use of medical devices for long-term outpatient care, such 
are dialysis patients, or patients assigned to a kidney transplant. These patients use 
medical devices for sterile intermittent catheterization, which reduce the risk of 
infections, administration of antibiotics and subsequent hospital admission.
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objeCtives: The costs for medical devices are growing due to civilization, chronic, 
oncological diseases as well as aging of the population. Reimbursement of medi-
cal devices covers also expensive medical devices for preparation and transmis-
sion of cytostatic, vacuum therapy system and medical devices for moist wound 
healing. Methods: The target of the work was to analyze the data from paid 
databases of Slovak authority National Center for Health Information that collects 
the outputs of provided health care. The data were focused on totally or partly 
reimbursed medical devices from public health insurance funds. The selected 
group were medical devices for bandaging and plasters (MDB). The most recent 
data were from 1.1. 2009 - 31.12. 2013. It was used basic and advanced statis-
tic processing by Microsoft Excel. Results: Referring to the Center for Health 
Information, in the observed period, the share of MDB on total consumption of 
MD decreased (MDB/MD2009= 12.88%; MDB/MD2013= 6.15%; Δ MDB/MD2009-
2013= -6.73%). The total quantitative consumption MDB also decreased (Δ 2009-
2013= -4 178 456pcs/-38.86%; max2009= 10 753 703pcs; min2012= 6 575 247pcs; 
AVG= 7 281 090pcs; Mean= 6 575 247pcs; SD= 1 978 697). The share of MDB on total 
reimbursement of MD increased (MDB/MD2009= 5.86%; MDB/MD2013= 10.55%; 
Δ MDB/MD2009-2013= 4.69%). The total reimbursement in the observed period 
increased (Δ 2009-2013= 8 986 420€ /119.44%; max2013= 16 510 294€ ; min2009= 7 523 
874€ ; AVG= 12 123 793€ ; Mean= 12 841 757€ ; SD= 3 674 676). The share of MDB on the 
patient supplements of MD decreased (MDB/MD2009= 5.66%; MDB/MD2013= 3.48%; 
Δ MDB/MD2009-2013= -2.18%). The total patient supplements slightly increased 
(Δ 2009-2013= 4 435€ /2.50%; max2013= 181 607€ ; min2009= 177 172€ ; AVG= 170 335€ ; 
Mean= 168 686€ ; SD= 8 842). ConClusions: According to the Health Insurance 
Funds annual reports the increase of costs was due to the introduction of treat-
ment using moist wound healing devices. The effectiveness of it is very high, 
since moisture is important for wound, granulation and epithelialization. Another 
advantage is prolonged interval between exchanges of MD, which significantly 
increases the quality of life of treated patients.
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objeCtives: The most important factor in the increased cost of medical devices 
(MD), especially in the group medical devices for people with ostomy, is a growing 
proportion of lifestyle diseases that require long-term use of medical devices. The 
medical devices for ostomies (MDO) are almost totally reimbursed from Health 
insurance funds totally. Methods: The target of the work was to analyse the data 
patients choose breast forms of character higher functional properties that increase 
the comfort after mastectomy.
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objeCtives: Companion devices are non-invasive devices that track, log or display 
essential information related to the safe and effective use of a drug or drug delivery 
device. By monitoring a patient’s personalized health data, mHealth allows for a 
greater degree of personalized and appropriate care provision for each patient, as 
well as collecting data to support decision making. Whilst analysts expect strong 
growth for the mHealth market globally, the perceived barriers, unclear reim-
bursement guidelines and absence of established pathways for adoption have 
limited its uptake To that end, the objectives of this research were to: A. Present 
potential reimbursement and adoption pathways for companion devices B. Assess 
perceived benefits & barriers by key stakeholders for the adoption of companion 
devices. Methods: A review of the literature published since 2010 and archived in 
PubMed and Medline, and clinical practice guidelines for common chronic diseases 
such as asthma/COPD was conducted. Additionally, health technology assessments 
(HTAs) related to mHealth and remote monitoring devices across the EU5 were 
reviewed. Results: Multiple routes to market were identified for mHealth, either 
as a stand-alone device or combining a drug and device. Each route has distinct 
challenges and benefits in terms of the assessment process and demonstrating 
value to stakeholders. ConClusions: As an emerging market segment, companion 
devices are expected to play a role along the full continuum of patient care: from 
prevention, diagnosis, treatment, to monitoring. Although reimbursement for com-
panion devices varies widely across Europe and continues to be challenging, several 
distinct initiatives in local health economies are demonstrating the willingness of 
clinicians and payers to adopt the new technology. As such, this study identified 
key issues that need to be addressed
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objeCtives: Turkish medical device sector has its own unique reimbursement and 
pricing setting. Pricing of medical devices is statutorily not regulated and freely 
set by manufacturers. However, Social Security Institution (SSI), the only compe-
tent authority for reimbursement, has been monitoring which devices to reim-
burse and regulate reimbursement prices through official SSI generic positive lists 
(since 2011). Objective of this study is to describe the system used to define ceiling 
prices for reimbursement, concurrently assessing its alteration. Methods: Health 
Implementation Communiqué (SUT) and public procurement law history regarding 
medical device pricing are analyzed. Results: Our study shows that government’s 
impact has increased on reimbursement prices as a result of increasing budgetary 
concerns. After Public Procurement Law initiated in 2008, medical devices were 
sold at manufacturer defined prices and Public Procurement System (PPS) sales 
records were used to find average procurement price, which was then determined 
as reimbursement price. After SSI’s first implementation of positive lists in 2011, 
“average or lowest price in PPS” is used again to define ceiling prices, yet there were 
still items without a price. Since October 2014, the control over the reimbursement 
prices has increased as all items on SUT positive lists were assigned a price and 
no more “average price rule” of past procurement records exists. However, it is not 
clear how these reimbursement prices are defined and transparently conducted 
currently. ConClusions: Reimbursement prices are determined according to a 
merely retrospective and detection of lowest or average price practice. Effectiveness 
of this practice is the main concern since the data on PPS by hospitals may be mis-
recorded by hospitals. It has been quite challenging to develop clear and fair criteria 
for reimbursement pricing. There remains an urgent need for productive discussion 
and collaboration between government and industry regarding reasonable funding, 
transparency, and clarity in the Turkish reimbursement pricing process
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objeCtives: The main factor influencing the costs development of medical devices 
for compression therapy of venous insufficiency (MDCT) are new diagnostic and 
therapeutic possibilities, expanding the range of medical devices with new func-
tions and a subgroup compression stockings containing silver. MDCT are reim-
bursed from Health insurance funds, but there is a presence of a high patient 
co-payment. Methods: The target of the work was to analyse the data from 
paid databases of Slovak authority National Center for Health Information that 
collects the outputs of provided health care. The data were focused on totally or 
partly reimbursed medical devices (MD) from public health insurance funds. The 
selected group was medical devices for compression therapy of venous insuffi-
ciency. The most recent data were from 1.1. 2009 - 31.12. 2013. It was used basic and 
advanced statistic processing by Microsoft Excel. Results: Referring to the National 
Center for Health Information, in the observed period, the share of MDCT on total 
consumption of MD stagnated (MDCT/MD2009= 0.09%; MDCT/MD2013= 0.12%; 
Δ MDCT/MD2009-2013= 0.04%). The total quantitative consumption MDCT increased 
(Δ 2009-2013= 51 760pcs/66.72%; max2013= 129 339pcs; min2009= 77 579pcs; AVG= 98 
910pcs; Mean= 95 987pcs; SD= 19 398). The share of MDCT on total reimbursement 
of MD stagnated (MDCT/MD2009= 1.39%; MDCT/MD2013= 1.53%; Δ MDCT/MD2009-
2013= 0.14%). The total reimbursement in the observed period increased (Δ 2009-
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objeCtives: Estimation of health gains associated to early diagnosis and treat-
ment of Chronic Obstructive Pulmonary Disease (COPD) in Portugal over a 20 year 
horizon. Methods: A stochastic individually based dynamic microsimulation 
model was built generating the evolution of diagnosed and undiagnosed COPD 
prevalences and severity distribution over four stages. Exacerbation frequencies 
and quality of life were associated to severity stages. Smoking habits were taken 
into account since smoking is the main risk-factor of COPD and smoking cessa-
tion is the most effective strategy to slowdown disease progression. The model 
defines annual probabilities for individuals to develop COPD according to sex, 
age and smoking habits. Individuals with COPD progress depending on disease 
stage and smoking behavior. Intervention health benefits were estimated as the 
difference between the status quo and an intervention scenario. In the interven-
tion scenario, smokers and ex-smokers aged 40 and over are screened in primary 
healthcare settings and selectively referred to smoking cessation programs. When 
diagnosed with COPD, patients progress more slowly and have higher quality of 
life due to medication and to less frequent exacerbation episodes. Health benefits 
of the intervention were estimated as the population life-years (LY) and quality-
adjusted life-years (QALYs) difference between the scenarios. Results: Over the 
20 years more than 2.8 million individuals are screened. With discounting at 5%, 
the intervention resulted in gains of 33,230 LY for men and 16,990 LY for women 
while incremental QALYs were 91,586 and 25,983 respectively. Serious exacerba-
tion events are 2.4% lower in the intervention scenario. ConClusions: These 
results show that early diagnosis and early treatment could lead to substantial 
health gains for the Portuguese population in a 20 year time horizon.
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objeCtives: The Medical Technologies Evaluation Programme (MTEP) was set up 
by NICE in 2009 to identify new medical devices and diagnostics that could improve 
patient experience and outcomes whilst driving healthcare efficiencies. The pur-
pose of this study was to examine whether procurement managers and key stake-
holders reviewing medical technologies in England and markets beyond are aware 
of NICE’s MTEP and whether they would use the review when considering uptake 
and use of a novel technology. Methods: A systematic review was undertaken 
for published literature on MTEP. Both an online survey and telephone interviews 
were used with procurement managers and key stakeholders to elicit further 
insight into the relevance of an MTEP review and its impact beyond England. 
Findings were collated and analysed thematically. Results: Procurement manag-
ers and key stakeholders reviewing medical technologies in England were aware 
of MTEP and used the outcomes from MTEP to assist in their decision making 
criteria. However, there are only a limited number of technologies that have gone 
through the programme and therefore its usefulness as a general resource is 
limited. Other markets often look for HTA having been performed on medical 
technologies and will broadly utilise data from MTEP where nothing has been 
performed in their local markets. Inconsistencies in healthcare costs are a major 
factor for not reviewing HTA from different markets. ConClusions: Procurement 
managers and key stakeholders reviewing medical technologies in England will 
use HTA, specifically NICE’s MTEP, if this data is available for the product they are 
reviewing. Stakeholders in markets outside of England will use this data as part of 
their assessment for uptake, but will look to local guidelines as a first step. NICE’s 
MTEP is viewed as a robust method for assessment of a technology; however, cost 
data is largely only applicable in England.
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objeCtives: Lung cancer is the most common cause of death from cancer world-
wide. Yet, screening for lung cancer remains controversial. We compared the risks 
and benefits of lung cancer screening with low-dose helical CT (LDCT) relative 
to chest x-ray (CXR). Concerns have been raised about recommending LDCT as 
a routine screening tool because of the potential harms, including cumulative 
radiation risks. Methods: We developed a decision analytic model to compare 
LDCT and CXR under alternative screening scenarios, and estimate the number of 
radiation-induced cancers due to LDCT and CXR exposure. The age and sex specific 
model was calibrated for Canada, using National Lung Screening Trial (NLST) and 
Prostate, Lung, Colorectal and Ovarian trial (PLCO) data. Three alternative strate-
gies were compared: regular screening with LDCT, screening with CXR, and no 
screening. Results: We compared radiation risks to estimated cancers prevented, 
using age and gender- specific projections. The average effective radiation dose for 
LDCT is only 22% (1.4 mSv) of the standard chest CT (7 mSv). However, the effective 
dose might be 20% to 23% higher for females than males. The average effective 
dose for CXR ranges 0.01 mSv - 0.06 mSv. LDCT showed a 20% reduction in lung 
cancer mortality compared to CXR. This translated into 3 fewer deaths from lung 
cancer per 1000 high-risk individuals screened with LDCT. However, more than 
90% of positive screened results were false positive findings. Over 97% of new 
lung cancer cases are in high-risk adults aged 50 years and older. ConClusions: 
Concerns have been raised about recommending LDCT as a routine screening tool 
for lung cancer. Our model addresses a number of public policy questions regard-
ing who should be targeted for screening and what the trade-offs are in terms of 
potential harms and benefits.
from paid databases of Slovak authority National Center for Health Information that 
collects the outputs of provided health care. The data were focused on totally or 
partly reimbursed medical devices from public health insurance funds. The selected 
group was medical devices for people with diabetes. The most recent data were 
from 1.1. 2009 - 31.12. 2013. It was used basic and advanced statistic processing by 
Microsoft Excel. Results: Referring to the Center for Health Information, in the 
observed period, the share of MDO on total consumption of MD stagnated (MDO/
MD2009= 4.71%; MDO/MD2013= 4.50%; Δ MDO/MD2009-2013= -0.21%). The total quan-
titative consumption MDO increased (Δ 2009-2013= 874 313pcs/22.22%; max2012= 4 
809 613pcs; min2009= 3 935 300pcs; AVG= 4 372 153pcs; Mean= 4 429 095pcs; 
SD= 346 405).The share of MDO on total reimbursementof MD stagnated (MDO/
MD2009= 8.31%; MDO/MD2013= 8.01%; Δ MDO/MD2009-2013= -0.30%). The total 
reimbursement in the observed period increased (Δ 2009-2013= 1 889 707€ /17.73%; 
max2013= 12 545 398€ ; min2010= 10 383 600€ ; AVG= 11 308 972€ ; Mean= 11 433 
975€ ; SD= 847 739). The share of MDO on the patient supplements of MD stagnated 
(MDO/MD2009= 0.44%; MDO/MD2013= 0.01%; Δ MDO/MD2009-2013= -0.43%). The total 
patient supplements decreased (Δ 2009-2013= -13 335 € /-97.03%; max2009= 13 743€ ; 
min2013= 408€ ; AVG= 4 571€ ; Mean= 1 243€ ; SD= 5 786). ConClusions: The ostomy 
medical devices and properly caring for ostomy can maintain a high quality of life 
for patients. Convenient reimbursement policy and almost none supplements for 
patients facilitates patient care of their own health.
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objeCtives: With a proportion of 57 to 80% leg ulcers are the most frequent 
chronic wounds next to decubitus and diabetic foot ulcers. Because of the high 
disease burden and the economic relevance, qualified and timely therapy is highly 
important. One of the constant aspects of causal therapy of venous leg ulcers is 
the medical compression therapy. Due to regional disparities in the treatment of 
venous leg ulcers, the question of economic effects arises. Methods: A discrete 
event simulation model for conducting health economic evaluations in patients 
with chronic wounds from the perspective of German statutory health insurances 
has been developed. It contains different treatment and financing options. The 
effectiveness of compression therapy has been observed with available data from 
clinical studies. Cost data were implemented from a cross-sectional study. The pro-
portion of patients with compression therapy is based on recent data of the Barmer 
GEK. Results: The average costs for compression therapy are 230 € per patient and 
year. A pilot run of the model analyses indicates significant differences in costs 
between the regions, depending on the utilisation of compression therapy. The 
highest total costs of chronic wound treatment were generated in the federal states 
with the lowest prescription rates of compression therapy and the lowest costs in 
those states with the highest utilisation of compression treatment. ConClusions: 
An increased proportion of patients with compression therapy is associated with 
an increase in the healing rate and interrelated cost savings for the German health 
care system.
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objeCtives: Upcoming changes in German healthcare regulation strengthen 
the need for real world evidence (RWE) analyses during market access of medical 
devices. RWE offers various opportunities to address different needs of diverse 
stakeholders of medical devices. Aim of this analysis was to identify the current 
status of RWE studies in the field of medical devices in Germany. Methods: A 
PubMed based literature review was performed. All publications in German/English 
language describing the use of medical devices in a real world setting in Germany 
were included. Publications were stratified by study design, type of RWE data and 
type of research question. Data categories were claims data, registry data and other 
data sources. Research questions were distinguished between brand-specific and 
non-brand-specific assessments. Results: In total, 39 publications were included 
in the analyses. Most of them used data from registries (44%), while claims data 
were analyzed in 18% of cases and other data sources were represented in 38%. The 
majority (74%) used a prospective study design. Two thirds of the studies analyzed 
data on a brand specific level whereas the remainder mainly distinguished between 
different types of medical devices. Registry data was mostly used to address brand 
specific research questions (88%) while all claims data based studies investigated 
research questions on a non-brand specific level. Common research questions were 
cost comparisons, survival analyses, and burden of disease. ConClusions: Various 
research questions can be answered by referring to RWE. Given the wide spectrum 
of medical devices, RWE is used only to a limited extent in the German setting, but 
is expected to become more important with changing regulation. However, careful 
considerations have to be made whether existing data sources can be utilized or 
new data needs to be generated to address specific research questions.
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